SynthesisCalcified tissue international2021
Prevalence of Sarcopenia and its Association with Antirheumatic Drugs in Middle-Aged and Older Adults with Rheumatoid Arthritis: A Systematic Review and Meta-analysis.
Synthesis in Calcified tissue international, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 2 syntheses or guidelines pooled it, 41 citations in OpenAlex.
- Effects of biologic and target synthetic disease-modifying anti-rheumatic drugs on sarcopenia in spondyloarthritis and rheumatoid arthritis: a systematic review and meta-analysis.Clinical rheumatology · 2023Pooled it
- The effect of disease-modifying anti-rheumatic drugs on skeletal muscle mass in rheumatoid arthritis patients: a systematic review with meta-analysis.Arthritis research & therapy · 2022Pooled it
- Trial
- Fall risk in rheumatoid arthritis revisited: A follow-up study focusing on sarcopenia and glucocorticoid use.Osteoporosis and sarcopenia · 2026Article
- Longitudinal Course of Muscle Status in Patients With Rheumatoid Arthritis.International journal of rheumatic diseases · 2026Article
- Sarcopenia, an independent predictor for all-cause mortality in rheumatoid arthritis: Insights from the NHANES database.Medicine · 2026Article
- Prevalence of sarcopenia in patients with rheumatoid arthritis: a cross-sectional study.RMD open · 2026Article
- Ultrasound evaluation of muscle quality in rheumatoid arthritis: a reliability study of the Spanish Ultrasound Muscle Assessment in Rheumatoid Arthritis (SpUMAR) score.Arthritis research & therapy · 2026Article
- Irisin and myostatin serum levels in patients with established rheumatoid arthritis: correlation with radiographic progression and lean body mass.Advances in rheumatology (London, England) · 2026Article
- Article
- Sarcopenia and sarcopenic obesity in rheumatoid arthritis patients: prevalence and their relationship with joint damage and functional impairment.Osteoporosis and sarcopenia · 2025Article
- Performance of Five Thai Versions of Sarcopenia Screening Questionnaires (SARC-F, SARC-CalF, MSRA-7, MSRA-5, and Modified MSRA-5) in Thai Rheumatoid Arthritis Patients: A Cross-Sectional Study.Journal of clinical medicine · 2025Article
- Late Onset Rheumatoid Arthritis.Aging and disease · 2025Review
- Construction and verification of a nomogram to estimate middle-aged and older individuals' susceptibility to sarcopenia.BMC musculoskeletal disorders · 2025Article
- Sarcopenia in Rheumatic Diseases: A Hidden Issue of Concern.Diseases (Basel, Switzerland) · 2025Review
- The Characteristic of Muscle Function for Sarcopenia in Patients with Rheumatoid Arthritis: A Large-Scale Real-World Cross-Sectional Study.Medicina (Kaunas, Lithuania) · 2025Article
- Drug risks associated with sarcopenia: a real-world and GWAS study.BMC pharmacology & toxicology · 2024Article
- The Effect of Rheumatoid Arthritis on Features Associated with Sarcopenia: A Mendelian Randomization Study.Calcified tissue international · 2024Article
- Drug-related sarcopenia as a secondary sarcopenia.Geriatrics & gerontology international · 2024Review
- Causal associations between autoimmune diseases and sarcopenia-related traits: a bi-directional Mendelian randomization study.Frontiers in genetics · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
To examine the prevalence of sarcopenia and its association with antirheumatic drugs in adults with rheumatoid arthritis (RA). This review was registered on PROSPERO and followed PRISMA guidelines. Electronic databases were searched for studies reporting on the prevalence of sarcopenia in adults with RA using any muscle index (muscle mass, strength and/or physical performance) and cutpoints as recommended by established criteria (EWGSOP1/2, AWGS, FNIH, SDOC). The secondary objective was to investigate the relationship between RA, antirheumatic drugs, and sarcopenia. Among 2240 middle-aged and older adults with RA (mean age: 47.7 ± 5.5 to 75.0 ± 6.2 years, 83.8% women), the pooled prevalence of low muscle mass/sarcopenia was 30.2% [95% confidence interval (CI) 24.2-36.2%; 16 studies; I
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.